Acquired Trisomy 21 - A Unique Cytogenetic Finding in T-Cell Acute Lymphoblastic Leukemia

Qurratulain Rizvi¹, Aisha Jamal¹, Jawad Hassan² and Tahir Shamsi¹,*

¹Department of Clinical Haematology National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.
²Department of Molecular Cytogenetics, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.

Abstract: Acute lymphoblastic leukemia (ALL), is a lymphoid neoplasm arising from lymphoid progenitors, broadly classified according to lineage into B-cell and T-cell ALL in which T-cell ALL constitutes a small proportion. We are reporting here a case of young female who was diagnosed as T-cell ALL using flow cytometry with acquired trisomy 21, identified on conventional cytogenetics, as a unique finding in this case.

Keywords: Acute lymphoblastic leukemia, Acquired trisomy 21, Cytogenetics, Karyotyping, Lymphadenopathy, T-cell ALL.

INTRODUCTION

Acute lymphoblastic leukemia (ALL) is a lymphoid neoplasm arising from lymphoid progenitors undergone sustained genetic insults and thereby leading to malignant transformation. It constitutes a major bulk of pediatric acute leukemia and accounts for about 20% cases of adult ALL. It comprises of two varieties, either derived from B lymphocytes which is known as B-Cell ALL or from T-lymphocytes known to be T-cell ALL. The incidence of T-cell ALL is around 20% and found to be occurring in mostly adult population. In general, the treatment outcome is favorable in B-cell ALL as compared to T-cell ALL. The role of cytogenetics is not well defined in T-cell ALL [1]. We are reporting here an unusual cytogenetic finding of acquired trisomy 21 found at baseline in a patient with T-cell ALL. Trisomy 21 is considered to be acquired when the phenotypic features pertinent to down syndrome are absent. There is proven enhanced leukemogenic potential in constitutional down syndrome [2]. The role of acquired trisomy 21 is relatively well documented in cases of B-cell ALL, but there is no such defined role in T-cell ALL.

CASE

A 22-year old girl with no known co-morbid was presented with complain of low grade fever for two months. There was no significant personal, past medical or family history. On examination, she was vitally stable with unremarkable systemic examinations. There was no lymphadenopathy or hepatos-plenomegaly. Her complete blood counts revealed Hb 6.4 g/dl, white cell count of 43.36 x 10⁹/L (absolute neutrophil count 0.47 x 10⁹/L and absolute lymphocyte count of 32.3 x 10⁹/L) with platelet count of 98 x 10⁹/L. Microscopic examination of peripheral smear showed medium to small size blast cells with scant agranular cytoplasm, having high nuclear/cytoplasmic ratio (Fig. 1).

Flowcytometry on peripheral blood demonstrated high expression of CD3, CD5, CD7, CD45, CD33 and CD34. TdT, cMPO, CD79a, CD13, CD117, CD20, CD10, and CD19 were negative, culminating the inference of T-cell ALL. The absence of Tdt is an exceptional finding but rare cases of TdT negative T-cell ALL have been reported in literature. Its absence confers a poor prognosis [3]. The expression of myeloid lineage in ALL has also been reported in 10-15% of cases. Pan myeloid antigen expression in lymphoid leukemia may suggest presence of Philadelphia chromosome. The cytogenetics analysis revealed a normal female karyotype with an additional chromosome 21 (47, XX, +21) in 09 metaphases, while 06 metaphases did not reveal any abnormality (Figs. 2, 3). Unfortunately, after detailed family counselling about treatment options and prognosis of disease, the family declined any curative treatment and opted for supportive care.

DISCUSSION

T-cell ALL is malignant neoplasm, constituting a small bulk of overall ALL. It originates from lymphoid tissue and belongs to T-cell lineage. It is a disease with variable biological heterogeneity. Despite of having an overall poor prognosis, along with other risk factors associated with this neoplasm, an insight into the cytogenetics and molecular studies...
may provide a ray of hope towards better treatment options. T-cell ALL cytogenetics usually reveals structural chromosomal aberrations, as determined by conventional karyotyping in about 50% of cases. Numerical changes are rare except for tetraploidy which has an incidence of 5% and imparts no clinical significance. Cytogenetics usually unravels normal karyotype. Cryptic abnormalities detected via fluorescence in situ hybridization (FISH) technique demonstrates deletions at 9p21 and at 1p32, translocation t(5;14) and rearrangements of T-cell receptor B(TCRB) at 7q34 and 9q34 breakpoints [4].

**Fig. (1).** Peripheral smear illustrating small sized blast cells having high nuclear to cytoplasmic ratio with scant, light basophilic agranular cytoplasm.

**Fig. (2).** Trisomy 21 identified in 9 out of 15 metaphases with 47 XX karyogram.
Acquired Trisomy 21 - A Unique Cytogenetic

According to the best of our knowledge, very scarce cases of acquired trisomy 21 have been reported in T-cell ALL in literature [5-7]. Acquired trisomy 21 is defined as gain of chromosome at locus 21 with lack of phenotypic features of typical Down’s Syndrome. It differs from constitutional down syndrome (DS) which is a factor that predisposes to paediatric leukemias. Acquired trisomy 21 has association with certain haematological malignancies such as myelodysplatic syndrome, myeloproliferative neoplasm, acute myeloid leukemia, but has never been documented as a sole abnormality. It has been observed in B-cell ALL as sole clonal abnormality, accounting for about 2% cases of paediatrics and less than 1% cases of adult ALL cases (essentially B lineage) [8]. There is prognostic ambiguity with regard to the prognostic significance of this acquired trisomy. In literature search, Cheng et al. [2] has clearly stated the poor prognosis imparted by the presence of trisomy 21 in ALL. Though this observation remains ambiguous as Atlas of genetics and cytogenetics in oncology and hematology reports trisomy 21 to confer a better overall survival when exist as a sole cytogenetic abnormality in childhood ALL; its role in adult ALL remains undetermined.

Prospective studies are needed to identify the role of numerical chromosomal abnormalities in T-cell ALL and therefore attempts can be made to tailor management approach.

CONFLICT OF INTEREST
Declared none.

ACKNOWLEDGEMENT
Declared none.

REFERENCES


© 2017 National journal of health sciences.
This is an open-access article.